[go: up one dir, main page]

AR109007A2 - Compuesto de oxazol y composición farmacéutica - Google Patents

Compuesto de oxazol y composición farmacéutica

Info

Publication number
AR109007A2
AR109007A2 ARP170101905A ARP170101905A AR109007A2 AR 109007 A2 AR109007 A2 AR 109007A2 AR P170101905 A ARP170101905 A AR P170101905A AR P170101905 A ARP170101905 A AR P170101905A AR 109007 A2 AR109007 A2 AR 109007A2
Authority
AR
Argentina
Prior art keywords
oxazol
methoxyphenyl
propan
ylmethyl
phenyl
Prior art date
Application number
ARP170101905A
Other languages
English (en)
Inventor
Tomonori Shibaata
Hidetaka Hiyama
Junpei Haruta
Hideki Kitagaki
Tetsuyuki Uno
Norifumi Sato
Masaya Kato
Minoru Okada
Original Assignee
Otsuka Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otsuka Pharma Co Ltd filed Critical Otsuka Pharma Co Ltd
Publication of AR109007A2 publication Critical patent/AR109007A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/04—Phosphoric diester hydrolases (3.1.4)
    • C12Y301/04012—Sphingomyelin phosphodiesterase (3.1.4.12)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Un compuesto de oxazol representado por la fórmula (1), en donde R¹ es un grupo fenilo que tiene dos sustituyentes seleccionados entre los siguientes (1-2), (1-3), (1-4), y (1-5): (1-2) grupos alcoxi C₁₋₆ sustituidos con halógeno o no sustituidos, (1-3) grupos alqueniloxi C₂₋₆, (1-4) grupos alquiniloxi C₂₋₆, (1-5) grupos cicloalquilo C₃₋₈-alcoxi C₁₋₆; R² es un grupo fenilo o un grupo piridilo, cada uno de los cuales puede tener de uno a dos sustituyentes seleccionados entre los siguientes (2-2), (2-3), (2-4), y (2-5): (2-2) grupos alcoxi C₁₋₆ sustituidos con halógeno o no sustituidos, (2-3) grupos alquilo C₁₋₆ sustituidos con halógeno o no sustituidos, (2-4) grupos alqueniloxi C₂₋₆, (2-5) átomos de halógeno; W es un grupo divalente representado por la fórmula (i): fórmula (i) -Y¹-A¹- en donde A¹ es un grupo alquileno C₁₋₆ que puede tener uno o más sustituyentes seleccionados del grupo constituido por grupos hidroxilo y grupos alcoxicarbonilo C₁₋₆, e Y¹ es -C(=O)-, o -C(=O)-N(R³)-, en donde R³ es un átomo de hidrógeno; caracterizado porque el compuesto de oxazol se selecciona de entre los siguientes compuestos (1) a (385): (1) N-[2-(3-benciloxi-4-metoxifenil)oxazol-4-ilmetil]-2-etoxibenzamida, (2) N-[2-(3-hidroxi-4-metoxifenil)-oxazol-4-ilmetil]-2-etoxibenzamida, (3) N-[2-(3-ciclopropilmetoxi-4-metoxifenil)oxazol-4-ilmetil]-2-etoxibenzamida, (4) N-{2-[4-metoxi-3-(2,2,2-trifluoroetoxi)fenil]oxazol-4-ilmetil}-2-etoxibenzamida, (5) N-[2-(3-butoxi-4-metoxifenil)oxazol-4-ilmetil]-2-etoxi-benzamida, (6) N-[2-(3-ciclopentiloxi-4-metoxifenil)oxazol-4-ilmetil]-2-etoxibenzamida, (7) N-{2-[3-(3-hidroxipropoxi)-4-metoxifenil]oxazol-4-ilmetil}-2-etoxibenzamida, (8) N-[2-(4-metoxi-3-(2-propiniloxi)fenil)oxazol-4-ilmetil]-2-etoxibenzamida, (9) N-[2-(3-etoxi-4-metoxifenil)oxazol-4-ilmetil]-2-etoxibenzamida, (10) N-[2-(4-metoxi-3-(2-oxiranilmetoxi)fenil)oxazol-4-ilmetil]-2-etoxibenzamida, (11) N-[2-(4-metoxi-3-propoxifenil)oxazol-4-ilmetil]-2-etoxi-benzamida, (12) N-[2-(3-isopropoxi-4-metoxifenil)oxazol-4-ilmetil]-2-etoxi-benzamida, (13) N-[2-(3-(3-buteniloxi)-4-metoxifenil)oxazol-4-ilmetil]-2-etoxibenzamida, (14) N-[2-(3-isobutoxi-4-metoxifenil)oxazol-4-ilmetil]-2-etoxi-benzamida, (15) N-{2-[4-metoxi-3-(3,3,3-trifluoropropoxi)fenil]oxazol-4-ilmetil}-2-etoxibenzamida, (16) N-[2-(3-benciloxi-4-metoxifenil)oxazol-4-ilmetil]-3-metil-picolinamida, (17) N-[2-(3-hidroxi-4-metoxifenil)oxazol-4-ilmetil]-3-metilpicolinamida, (18) N-[2-(3-ciclopentiloxi-4-metoxifenil)oxazol-4-ilmetil]-3-metilpicolinamida, (19) N-{2-[4-metoxi-3-(2,2,2-trifluoro-etoxi)fenil]oxazol-4-ilmetil}-3-metilpicolinamida, (20) N-[2-(3-etoxi-4-metoxifenil)oxazol-4-ilmetil]-3-metilpicolinamida, (21) N-[2-(3-aliloxi-4-metoxifenil)oxazol-4-ilmetil]-3-metilpicolinamida, (22) N-{2-[3-(indan-2-iloxi)-4-metoxifenil]oxazol-4-ilmetil}-3-metil-picolinamida, (23) N-[2-(3-benciloxi-4-metoxifenil)-oxazol-4-ilmetil]-2-trifluorometilbenzamida, (24) N-[2-(3-hidroxi-4-metoxifenil)oxazol-4-ilmetil]-2-trifluorometilbenzamida, (25) N-[2-(3-ciclopropilmetoxi-4-metoxifenil)oxazol-4-ilmetil]-2-trifluorometilbenzamida, (26) N-{2-[3-(3-hidroxipropoxi)-4-metoxifenil]oxazol-4-ilmetil}-2-trifluorometilbenzamida, (27) N-[2-(3-benciloxi-4-metoxifenil)oxazol-4-ilmetil]-3-etoxipicolinamida, (28) N-[2-(3-hidroxi-4-metoxifenil)-oxazol-4-ilmetil]-3-etoxipicolinamida, (29) N-[2-(3-ciclopentiloxi-4-metoxifenil)-oxazol-4-ilmetil]-3-etoxipicolinamida, (30) N-[2-(3-benciloxi-4-metoxifenil)oxazol-4-ilmetil]-2-(2,2,2-trifluoroetoxi)benzamida, (31) N-[2-(3-hidroxi-4-metoxifenil)oxazol-4-ilmetil]-2-(2,2,2-trifluoroetoxi)-benzamida, (32) N-[2-(3-ciclopropilmetoxi-4-metoxifenil)oxazol-4-ilmetil]-2-(2,2,2-trifluoroetoxi)benzamida, (33) N-[2-(3-benciloxi-4-metoxifenil)oxazol-4-ilmetil]-2-metoxibenzamida, (34) N-[2-(3-hidroxi-4-metoxifenil)oxazol-4-ilmetil]-2-metoxibenzamida, (35) N-[2-(3-ciclopentiloxi-4-metoxifenil)-oxazol-4-ilmetil]-2-metoxibenzamida, (36) N-[2-(3-ciclopropilmetoxi-4-metoxifenil)oxazol-4-ilmetil]-3-metilpicolinamida, (37) N-[2-(3-ciclopropilmetoxi-4-metoxifenil)oxazol-4-ilmetil]-2-isopropoxibenzamida, (38) N-[2-(3-ciclopropilmetoxi-4-metoxifenil)oxazol-4-ilmetil]-2-metilbenzamida, (39) N-[2-(3-ciclopropilmetoxi-4-metoxifenil)oxazol-4-ilmetil]-2-etilbenzamida, (40) N-[2-(3-ciclopropilmetoxi-4-metoxifenil)oxazol-4-ilmetil]-2-clorobenzamida, (41) N-[2-(3-ciclopropilmetoxi-4-metoxifenil)oxazol-4-ilmetil]-5-fluoro-2-metoxibenzamida, (42) N-[2-(3-ciclopropilmetoxi-4-metoxifenil)oxazol-4-ilmetil]-4-fluoro-2-metoxibenzamida, (43) N-[2-(3-ciclopropilmetoxi-4-metoxifenil)oxazol-4-ilmetil]-2-fluoro-6-metoxibenzamida, (44) N-[2-(3-ciclopropilmetoxi-4-metoxifenil)oxazol-4-ilmetil]-2-metilsulfanilbenzamida, (45) N-[2-(3-ciclopropilmetoxi-4-metoxifenil)oxazol-4-ilmetil]-3-hidroxipicolinamida, (46) N-[2-(3-ciclopropilmetoxi-4-metoxifenil)oxazol-4-ilmetil]-2-metoxibenzamida, (47) N-[2-(3-ciclopropilmetoxi-4-metoxifenil)oxazol-4-ilmetil]-2-trifluorometoxibenzamida, (48) N-[2-(3-ciclopropilmetoxi-4-metoxifenil)oxazol-4-ilmetil]-2-propoxibenzamida, (49) N-[2-(3-ciclopropilmetoxi-4-metoxifenil)oxazol-4-ilmetil]-pirazina-2-carboxamida, (50) N-[2-(3-ciclopropilmetoxi-4-metoxifenil)oxazol-4-ilmetil]-3-etoxipicolinamida, (51) N-[2-(3-ciclopropilmetoxi-4-metoxifenil)oxazol-4-ilmetil]-2-butoxibenzamida, (52) N-[2-(3-ciclopropilmetoxi-4-metoxifenil)oxazol-4-ilmetil]-2-isobutoxibenzamida, (53) N-[2-(3-ciclopropilmetoxi-4-metoxifenil)oxazol-4-ilmetil]-3-isopropoxipicolinamida, (54) N-[2-(3-ciclopropilmetoxi-4-metoxifenil)oxazol-4-ilmetil]-2-etilsulfanilbenzamida, (55) N-[2-(3-ciclopropilmetoxi-4-metoxifenil)oxazol-4-ilmetil]-1-óxidopicolinamida, (56) N-[2-(3-ciclopropilmetoxi-4-metoxifenil)oxazol-4-ilmetil]-2,6-dimetoxibenzamida, (57) N-[2-(3-ciclopropilmetoxi-4-metoxifenil)oxazol-4-ilmetil]-3-metoxipicolinamida, (58) N-[2-(3-ciclopropilmetoxi-4-metoxifenil)oxazol-4-ilmetil]-3-isobutoxipicolinamida, (59) N-[2-(3-ciclopropilmetoxi-4-metoxifenil)oxazol-4-ilmetil]-2-metilnicotinamida, (60) N-[2-(3-ciclopropilmetoxi-4-metoxifenil)oxazol-4-ilmetil]-2-metano-sulfonilbenzamida, (61) N-2-(3-ciclopropilmetoxi-4-metoxifenil)oxazol-4-ilmetil]-3-propoxipicolinamida, (62) N-[2-(3-isobutoxi-4-metoxifenil)oxazol-4-ilmetil]-3-metilpicolinamida, (63) N-[2-(3-isobutoxi-4-metoxifenil)oxazol-4-ilmetil]-2-metoxi-benzamida, (64) N-[2-(3-isobutoxi-4-metoxifenil)oxazol-4-ilmetil]-2-metil-sulfanilbenzamida, (65) N-[2-(3-isobutoxi-4-metoxifenil)oxazol-4-ilmetil]-3-etoxi-picolinamida, (66) N-[2-(3-isobutoxi-4-metoxifenil)oxazol-4-ilmetil]-2-metoxi-4-fluorobenzamida, (67) N-[2-(3-isobutoxi-4-metoxifenil)oxazol-4-ilmetil]-2-iso-propoxibenzamida, (68) N-[2-(3-isobutoxi-4-metoxifenil)oxazol-4-ilmetil]-2-fluoro-6-metoxibenzamida, (69) N-[2-(3-isobutoxi-4-metoxifenil)oxazol-4-ilmetil]-3-metoxi-picolinamida, (70) N-[2-(3-isobutoxi-4-metoxifenil)oxazol-4-ilmetil]-3-isobutoxi-picolinamida, (71) N-[2-(3-isobutoxi-4-metoxifenil)oxazol-4-ilmetil]-2-propoxibenzamida, (72) N-[2-(3-isobutoxi-4-metoxifenil)oxazol-4-ilmetil]-2-butoxibenzamida, (73) N-[2-(3-isobutoxi-4-metoxifenil)oxazol-4-ilmetil]-2-iso-butoxibenzamida, (74) N-[2-(3-isobutoxi-4-metoxifenil)oxazol-4-ilmetil]-3-iso-propoxipicolinamida, (75) N-[2-(3-isobutoxi-4-metoxifenil)oxazol-4-ilmetil]-2-metil-nicotinamida, (76) N-{2-[4-metoxi-3-(2,2,2-trifluoroetoxi)fenil]oxazol-4-ilmetil}-3-metoxi-picolinamida, (77) N-{2-[4-metoxi-3-(2,2,2-trifluoroetoxi)fenil]oxazol-4-il-metil}-3-etoxipicolinamida, (78) N-{2-[4-metoxi-3-(2,2,2-trifluoroetoxi)fenil]oxazol-4-il-metil}-2-metoxibenzamida, (79) N-{2-[4-metoxi-3-(2,2,2-trifluoroetoxi)fenil]oxazol-4-il-metil}-2-metilobenzamida, (80) N-{2-[4-metoxi-3-(2,2,2-trifluoroetoxi)fenil]oxazol-4-il-metil}-2-propoxibenzamida, (81) N-{2-[4-metoxi-3-(2,2,2-trifluoroetoxi)fenil]oxazol-4-il-metil}-2-isopropoxibenzamida, (82) N-{2-[4-metoxi-3-(2,2,2-trifluoroetoxi)fenil]oxazol-4-il-metil}-4-cloro-2-metoxibenzamida, (83) N-{2-[3-ciclopropilmetoxi-4-(2,2,2-trifluoroetoxi)fenil]oxazol-4-ilmetil}-2-etoxibenzamida (84) N-{2-[3-ciclopropilmetoxi-4-(2,2,2-trifluoroetoxi)fenil]oxazol-4-il-metil}-3-metilpicolina, (85) N-[2-(3,4-dietoxifenil)oxazol-4-ilmetil]-2-propoxibenzamida, (86) N-[2-(3,4-dietoxifenil)oxazol-4-ilmetil]-2-trifluorometilbenzamida, (87) N-[2-(3,4-dietoxifenil)oxazol-4-ilmetil]picolinamida, (88)N-[2-(3,4-dietoxifenil)oxazol-4-ilmetil]-2-etoxibenzamida, (89)N-[2-(3,4-dietoxifenil)oxazol-4-ilmetil]-4-etoxibenzamida, (90) N-[2-(3,4-dietoxifenil)oxazol-4-ilmetil]-5-metoxi-2-trifluoro-metoxibenzamida, (91) N-[2-(3,4-dietoxifenil)oxazol-4-ilmetil]-3-etoxibenzamida, (92) N-[2-(3,4-dimetoxifenil)oxazol-4-ilmetil]-2-etoxibenzamida, (93) N-[2-(3,4-dimetoxifenil)oxazol-4-ilmetil]-2-etilbenzamida, (94) N-[2-(3,4-dimetoxifenil)oxazol-4-ilmetil]-3-metilpicolinamida, (95) N-[2-(3,4-dimetoxifenil)oxazol-4-ilmetil]-3-metoxipicolinamida, (96) N-[2-(3-benciloxi-4-difluorometoxifenil)oxazol-4-ilmetil]-3-metilpicolinamida, (97) N-[2-(4-difluorometoxi-3-hidroxifenil)oxazol-4-ilmetil]-3-etil-picolinamida, (98) N-[2-(3-ciclopropilmetoxi-4-difluorometoxifenil)oxazol-4-ilmetil]-3-metilopicolinamida, (99) N-[2-(3-ciclopropilmetoxi-4-metoxifenil)oxazol-4-ilmetil]isoquinolina-1-carboxamida, (100) 2-[2-(3-benciloxi-4-metoxifenil)oxazol-4-ilmetilo]-3-(2-etoxi-fenil)-3-oxopropionato, (101) 1-(2-etoxifenil)-3-[2-(3-hidroxi-4-metoxifenil)-oxazol-4-il]propan-1-ona, (102) 3-[2-(3-ciclopropilmetoxi-4-metoxifenil)oxazol-4-il]-1-(2-etoxifenil)-propan-1-ona, (103) 3-[2-(3-etoxi-4-metoxifenil)oxazol-4-il]-1-(2-etoxifenil)-propan-1-ona, (104) 3-[2-(3-aliloxi-4-metoxifenil)oxazol-4-il]-1-(2-etoxifenil)propan-1-ona, (105) 3-[2-(3-ciclopentiloxi-4-metoxifenil)oxazol-4-il]-1-(2-etoxi-fenil)propan-1-ona, (106) 3-[2-(3-isobutoxi-4-metoxifenil)oxazol-4-il]-1-(2-etoxi-fenil)-propan-1-ona, (107) 1-(2-etoxifenil)-3-[2-(4-metoxi-3-propoxifenil)oxazol-4-il]propan-1-ona, (108) 3-[2-(3-(3-buteniloxi)-4-metoxifenil)oxazol-4-il]-1-(2-etoxifenil)propan-1-ona, (109) 3-[2-(3-butoxi-4-metoxifenil)oxazol-4-il]-1-(2-etoxifenil)-propan-1-ona, (110) 1-(2-etoxifenil)-3-[2-(4-metoxi-3-(2-propeniloxi)fenil)oxazol-4-il]propan-1-ona, (111) 1-(2-etoxifenil)-3-[2-(3-isopropoxi-4-metoxifenil)oxazol-4-il]propan-1-ona, (112) 1-(2-etoxifenil)-3-{2-[4-metoxi-3-(2,2,2-trifluoroetoxi)-fenil]oxazol-4-il}propan-1-ona, (113) 3-[2-(3-ciclohexilmetoxi-4-metoxifenil)oxazol-4-il]-1-(2-etoxifenil)propan-1-ona, (114) 3-[2-(3-ciclopentilmetoxi-4-metoxifenil)oxazo1-4-il]-1-(2-etoxifenil)propan-1-ona, (115) 1-(2-etoxifenil)-3-[2-(4-metoxi-3-(4-penteniloxi)fenil)-oxazol-4-il]propan-1-ona, (116) 3-[2-(3-ciclobutilmetoxi-4-metoxifenil)oxazol-4-il]-1-(2-etoxifenil)propan-1-ona, (117) 1-(2-etoxifenil)-3-{2-[4-metoxi-3-(3-metil-2-buteniloxi)-fenil]-oxazol-4-il}propan-1-ona, (118) 3-{2-[3-(2-ciclohexeniloxi)-4-metoxifenil]oxazol-4-il}-1-(2-etoxifenil)propan-1-ona, (119) 1-(2-etoxifenil)-3-[2-(4-metoxi-3-fenetiloxifenil)oxazol-4-il]propan-1-ona, (120) 1-(2-etoxifenil)-3-{2-[4-metoxi-3-(3-fenilpropoxi)fenilo]-oxazol-4-il}propan-1-ona, (121) 3-{2-[3-(2-ciclopropiletoxi)-4-metoxifenil]oxazol-4-il}-1-(2-etoxifenil)propan-1-ona, (122) 3-{2-[3-(2-ciclopentiletoxi)-4-metoxifenil]oxazol-4-il}-1-(2-etoxifenil)propan-1-ona, (123) 3-{2-[3-ciclopropilmetoxi-4-(2,2,2-trifluoroetoxi)-fenil]-oxazol-4-il}-1-(3-metoxipiridin-2-il)propan-1-ona, (124) 2-[2-(3-benciloxi-4-metoxifenil)oxazol-4-ilmetil]-3-(3-metoxi-piridin-2-il)-3-oxopropionato, (125) 3-[2-(3-hidroxi-4-metoxifenil)oxazol-4-il]-3-(3-metoxipiridin-2-il)propan-1-ona, (126) 3-[2-(3-ciclopropilmetoxi-4-metoxifenil)oxazol-4-il]-3-(3-metoxi-piridin-2-il)propan-1-ona, (127) 3-[2-(3-isobutoxi-4-metoxifenil)oxazol-4-il]-3-(3-metoxi-piridin-2-il)propan-1-ona, (128) 3-[2-(3-ciclopentiloxi-4-metoxifenil)oxazol-4-il]-1-(3-metoxipiridin-2-il)propan-1-ona, (129) 1-(3-metoxipiridin-2-il)-3-{2-[4-metoxi-3-(2,2,2-trifluoroetoxi)fenil]oxazol-4-il}propan-1-ona, (130) 2-[2-(3-benciloxi-4-metoxifenil)oxazol-4-ilmetil]-3-(3-etoxipiridin-2-il)-3-oxopropionato, (131) 1-(3-etoxipiridin-2-il)-3-[2-(3-hidroxi-4-metoxifenil)oxazol-4-il]propan-1-ona, (132) 3-[2-(3-ciclopentiloxi-4-metoxifenil)oxazol-4-il]-1-(3-etoxipiridin-2-il)propan-1-ona, (133) 3-[2-(3-ciclopropilmetoxi-4-metoxifenil)oxazol-4-il]-1-(3-etoxipiridin-2-il)propan-1-ona, (134) 1-(3-etoxipiridin-2-il)-3-[2-(3-isobutoxi-4-metoxifenil)-oxazol-4-il]propan-1-ona, (135) 2-[2-(3-benciloxi-4-metoxifenil)oxazol-4-ilmetil]-3-(3-metilpiridin-2-il)-3-oxo-propionato, (136) 3-[2-(3-hidroxi-4-metoxifenil)oxazol-4-il]-1-(3-metilpiridin-2-il)-propan-1-ona, (137) 3-[2-(3-ciclopropilmetoxi-4-metoxifenil)oxazol-4-il]-1-(3-metilpiridin-2-il)propan-1-ona, (138) 3-[2-(3-etoxi-4-metoxifenil)oxazol-4-il]-1-(3-metilpiridin-2-il)propan-1-ona, (139) 3-[2-(3-isopropoxi-4-metoxifenil)oxazol-4-il]-1-(3-metilpiridin-2-il)propan-1-ona, (140) 3-[2-(3-aliloxi-4-metoxifenil)oxazol-4-il]-1-(3-metilpiridin-2-il)propan-1-ona, (141) 3-[2-(3-ciclobutilmetoxi-4-metoxifenil)oxazol-4-il]-1-(3-metilpiridin-2-il)propan-1-ona, (142) 3-[2-(3-isobutoxi-4-metoxifenil)oxazol-4-il]-1-(3-metilpiridin-2-il)propan-1-ona, (143) 3-[2-(4-metoxi-3-propoxifenil)oxazol-4-il]-1-(3-metilpridin-2-il)propan-1-ona, (144) 3-[2-(3-ciclopentiloxi-4-metoxifenil)oxazol-4-il]-1-(3-metilpiridina-2-il)propan-1-ona, (145) 3-[2-(4-metoxi-3-(2-propeniloxi)fenil)oxazol-4-il]-1-(3-metilpiridin-2-il)propan-1-ona, (146) 3-[2-(3-(3-buteniloxi)-4-metoxifenil)oxazol-4-il]-1-(3-metilpiridin-2-il)propan-1-ona, (147) 3-[2-(3-butoxi-4-metoxifenil)oxazol-4-il]-1-(3-metilpiridin-2-il)propan-1-ona, (148) 3-[2-(3-ciclohexilmetoxi-4-metoxifenil)oxazol-4-il]-1-(3-metilpiridin-2-il)propan-1-ona, (149) 3-[2-(4-metoxi-3-(4-penteniloxi)fenil)oxazol-4-il]-1-(3-metilpiridin-2-il)propan-1-ona, (150) 3-[2-(4-metoxi-3-fenetiloxifenil)oxazol-4-il]-1-(3-metilpiridin-2-il)propan-1-ona, (151) 3-{2-[4-metoxi-3-(3-fenilpropoxi)fenil]oxazol-4-il}-1-(3-metilpiridin-2-il)propan-1-ona, (152) 3-[2-(3-ciclopentilmetoxi-4-metoxifenil)oxazol-4-il]-1-(3-metilpiridin-2-il)propan-1-ona, (153) 3-{2-[3-(2-ciclopropiletoxi)-4-metoxifenil]oxazol-4-il}-1-(3-metilpiridin-2-il)propan-1-ona, (154) 3-{2-[3-(2-ciclopentiletoxi)-4-metoxifenil]oxazol-4-il}-1-(3-metilpiridin-2-il)propan-1-ona, (155) 3-{2-[4-metoxi-3-(2,2,2-trifluoroetoxi)fenil]oxazol-4-il}-1-(3-metilpiridin-2-il)propan-1-ona, (156) 3-{2-[4-metoxi-3-(3-metil-2-buteniloxi)fenil]oxazol-4-il}-1-(3-metilpiridin-2-il)propan-1-ona, (157) 3-{2-[3-(2-ciclohexeniloxi)-4-metoxifenil]oxazol-4-il}-1-(3-metilpiridin-2-il)propan-1-ona, (158) 3-[2-(3-ciclohexiloxi-4-metoxifenil)oxazol-4-il]-1-(3-metilpiridin-2-il)propan-1-ona, (159) 3-{2-[3-(indan-2-iloxi)-4-metoxifenil]oxazol-4-il}-1-(3-metilpiridin-2-il)propan-1-ona, (160) 2-[2-(3-benciloxi-4-metoxifenil)oxazol-4-ilmetil]-3-oxo-3-piridin-2-ilpropionato, (161) 3-[2-(3-hidroxi-4-metoxifenil)oxazol-4-il]-1-(piridin-2-il)propan-1-ona, (162) 3-[2-(3-ciclobutilmetoxi-4-metoxifenil)oxazol-4-il]-1-(piridin-2-il)propan-1-ona, (163) 3-[2-(4-metoxi-3-(4-penteniloxi)fenil)oxazol-4-il]-1-(piridin-2-il)propan-1-ona, (164) 1-(2-aliloxifenil)-3-[2-(3-benciloxi-4-metoxifenil)oxazol-4-il]propan-1-ona, (165) 3-[2-(3-hidroxi-4-metoxifenil)-oxazol-4-il]-1-(2-hidroxifenil)propan-1-ona, (166) 3-[2-(3-aliloxi-4-metoxifenil)oxazol-4-il]-1-(2-aliloxifenil)propan-1-ona, (167) 2-[2-(3-benciloxi-4-metoxifenil)oxazol-4-ilmetil]-3-(2-metoxifenil)-3-oxopropionato, (168) 3-[2-(3-hidroxi-4-metoxifenil)oxazol-4-il]-1-(2-metoxifenil)propan-1-ona, (169) 3-[2-(3-isopropoxi-4-metoxifenil)-oxazol-4-il]-1-(2-metoxifenil)propan-1-ona, (170) 3-[2-(3-ciclopropilmetoxi-4-metoxifenil)oxazol-4-il]-1-(2-metoxifenil)propan-1-ona, (171) 3-[2-(3-ciclopentiloxi-4-metoxifenil)oxazol-4-il]-1-(2-metoxi-fenil)propan-1-ona, (172) 3-[2-(3-etoxi-4-metoxifenil)oxazol-4-il]-1-(2-metoxifenil)-propan-1-ona, (173) 3-[2-(3-isobutoxi-4-metoxifenil)oxazol-4-il]-1-(2-metoxi-fenil)-propan-1-ona, (174) 3-[2-(3-aliloxi-4-metoxifenil)oxazol-4-il]-1-(2-metoxifenil)-propan-1-ona, (175) 1-(2-metoxifenil)-3-{2-[4-metoxi-3-(2,2,2-trifluoroetoxi)-fenil]oxazol-4-il}propan-1-ona, (176) 3-[2-(3-ciclopropilmetoxi-4-metoxifenil)oxazol-4-il]-1-(2-hidroxifenil)propan-1-ona, (177) 1-(2-aliloxifenil)-3-[2-(3-ciclopropilmetoxi-4-metoxifenil)-oxazol-4-il]propan-1-ona, (178) 1-(2-aliloxifenil)-3-[2-(3,4-dietoxifenil)oxazol-4-il]propan-1-ona, (179) 1-(2-clorofenil)-3-[2-(3-ciclopropilmetoxi-4-metoxifenil)-oxazol-4-il]propan-1-ona, (180) 2-[2-(3,4-dietoxifenil)oxazol-4-ilmetil]-3-(3-metilpiridin-2-il)-3-oxopropionato, (181) 3-[2-(3,4-dietoxifenil)oxazol-4-il]-1-(3-metilpiridin-2-il)propan-1-ona, (182) 3-[2-(3,4-dietoxifenil)oxazol-4-il]-1-(2-etoxifenil)propan-1-ona, (183) 3-[2-(3,4-dietoxifenil)oxazol-4-il]-1-(3-etoxipiridin-2-il)-propan-1-ona, (184) 3-[2-(3,4-dietoxifenil)oxazol-4-il]-1-(3-etoxifenil)propan-1-ona, (185) 3-[2-(3,4-dietoxifenil)oxazol-4-il]-1-(4-etoxifenil)propan-1-ona, (186) 2-[2-(3,4-bisbenciloxifenil)oxazol-4-ilmetil]-3-(3-metilpiridin-2-il)-3-oxopropionato, (187) 3-[2-(3,4-dihidroxifenil)oxazol-4-ilmetil]-1-(3-metilpiridin-2-il)-propan-1-ona, (188) 3-{2-[3,4-bis-(2,2,2-trifluoroetoxi)fenil]oxazol-4-il}-1-(3-metilpiridin-2-il)-propan-1-ona, (189) 1-(2-aliloxifenil)-3-[2-(3-etoxi-4-metoxifenil)oxazol-4-il]propan-1-ona, (190) 3-[2-(4-benciloxi-3-etoxifenil)oxazol-4-il]-1-(2-etoxifenil)propan-1-ona, (191) 3-[2-(3-etoxi-4-hidroxifenil)oxazol-4-il]-1-(2-etoxi-fenil)-propan-1-ona, (192) 3-[2-(3-etoxi-4-isopropoxifenil)oxazol-4-il]-1-(2-etoxifenil)-propan-1-ona, (194) 3-[2-(3-hidroxi-4-metoxifenil)oxazol-4-il]-1-(2-propoxifenil)propan-1-ona, (195) 3-[2-(3-etoxi-4-metoxifenil)oxazol-4-il]-1-(2-propoxifenil)propan-1-ona, (196) 3-[2-(3-ciclopentiloxi-4-metoxifenil)-oxazol-4-il]-1-(2-propoxifenil)propan-1-ona, (197) 3-[2-(3-isopropoxi-4-metoxifenil)oxazol-4-il]-1-(2-propoxifenil)propan-1-ona, (198) 3-[2-(3-ciclopropilmetoxi-4-metoxifenil)oxazo1-4-il]-1-(2-propoxifenil)propan-1-ona, (199) 3-[2-(3-(3-buteniloxi)-4-metoxifenil)oxazol-4-il]-1-(2-propoxi-fenil)-propan-1-ona, (200) 3-[2-(3-aliloxi-4-metoxifenil)oxazol-4-il]-1-(2-propoxifenil)propan-1-ona, (201) 3-[2-(3-ciclobutilmetoxi-4-metoxifenil)oxazol-4-il]-1-(2-propoxifenil)propan-1-ona, (203) 3-{2-[4-metoxi-3-(2,2,2-trifluoroetoxi)fenil]oxazol-4-il}-1-(2-propoxifenil)propan-1-ona, (205) 3-[2-(3,4-dietoxifenil)oxazol-4-il]-1-(2-propoxi-fenil)propan-1-ona, (207) 3-[2-(3-hidroxi-4-metoxifenil)-oxazol-4-il]-1-(2-isoprepoxifenil)propan-1-ona, (208) 3-[2-(3-ciclopropilmetoxi-4-metoxifenil)oxazol-4-il]-1-(2-isopropoxifenil)propan-1-ona, (209) 3-[2-(3-etoxi-4-metoxifenil)oxazol-4-il]-1-(2-isopropoxifenil)propan-1-ona, (210) 3-[2-(3-isopropoxi-4-metoxifenil)oxazol-4-il]-1-(2-isopropoxi-fenil)propan-1-ona, (211) 3-[2-(3-aliloxi-4-metoxifenil)oxazol-4-il]-1-(2-isopropoxi-fenil)-propan-1-ona, (212) 3-[2-(3-(3-buteniloxi)-4-metoxifenil)oxazol-4-il]-1-(2-isopropoxifenil)propan-1-ona, (213) 1-(2-isopropoxifenil)-3-{2-[4-metoxi-3-(2,2,2-trifluoroetoxi)fenil]oxazol-4-il}-propan-1-ona, (214) 3-[2-(3-ciclobutilmetoxi-4-metoxifenil)oxazol-4-il]-1-(2-isopropoxifenil)propan-1-ona, (216) 3-[2-(3,4-dietoxifenil)oxazol-4-il]-1-(2-isopropoxi-fenil)propan-1-ona, (218) 3-[2-(3,4-dietoxifenil)oxazol-4-il]-1-o-tolilpropan-1-ona, (220) 3-[2-(3-hidroxi-4-metoxifenil)oxazol-4-il]-1-o-tolilpropan-1-ona, (221) 3-[2-(3-ciclopropilmetoxi-4-metoxifenil)oxazol-4-il]-1-o-tolilpropan-1-ona, (223) 1-(2-hidroxifenil)-3-[2-(3-isopropoxi-4-metoxifenil)-oxazol-4-il]propan-1-ona, (224) 1-(2-aliloxifenil)-3-[2-(3-isopropoxi-4-metoxifenil)oxazol-4-il]propan-1-ona, (225) 3-[2-(3-etoxi-4-metoxifenil)oxazol-4-il]-1-o-tolilpropan-1-ona, (226) 3-[2-(3-aliloxi-4-metoxifenil)oxazol-4-il]-1-o-tolilpropan-1-ona, (227) 3-[2-(3-isopropoxi-4-metoxifenil)oxazol-4-il]-1-o-tolilpropan-1-ona, (228) 3-[2-(3-benciloxi-4-difluorometoxifenil)oxazol-4-il]-1-(2-etoxifenil)-propan-1-ona, (229) 3-[2-(4-difluorometoxi-3-hidroxifenil)oxazol-4-il]-1-(2-etoxifenil)-propan-1-ona, (230) 3-[2-(4-difluorometoxi-3-isopropoxifenil)oxazol-4-il]-1-(2-etoxi-fenil)-propan-1-ona, (231) 3-[2-(3-benciloxi-4-metoxifenil)oxazol-4-il]-1-(2-metoximetoxifenil)propan-1-ona, (232) 3-[2-(3-hidroxi-4-metoxifenil)oxazol-4-il]-1-(2-metoxi-metoxifenilo)propan-1-ona, (233) 3-[2-(3-isopropoxi-4-metoxifenil)oxazol-4-il]-1-(2-metoximetoxifenil)propan-1-ona, (234) 3-[2-(3-etoxi-4-metoxifenil)oxazol-4-il]-1-[2-(2,2,2-trifluoroetoxi)fenil]propan-1-ona, (235) 3-[2-(3-etoxi-4-metoxifenil)oxazol-4-il]-1-(2-trifluorometoxi-fenil)-propan-1-ona, (236) 3-[2-(3,4-dietoxifenil)oxazol-4-il]-1-pirrolidin-1-il-propan-1-ona, (237) 3-[2-(3,4-dietoxifenil)oxazol-4-il]-1-(3-hidroxipirrolidin-1-il)propan-1-ona, (238) 3-[2-(4-benciloxi-3-metoxifenil)-oxazol-4-il]-1-pirrolidin-1-ilpropan-1-ona, (239) 3-[2-(4-hidroxi-3-metoxifenil)oxazol-4-il]-1-pirrolidin-1-ilpropan-1-ona, (240) 3-[2-(4-etoxi-3-metoxifenil)oxazol-4-il]-1-pirrolidin-1-ilpropan-1-ona, (241) N-[2-(3-ciclopropilmetoxi-4-metoxifenil)oxazol-4-ilmetil]-N-metil-2-trifluorometil-benzamida, (242) N-[2-(3,4-dimetoxifenil)oxazol-4-ilmetil]-2-etoxi-N-metilbenzamida, (243) N-{2-[2-(3,4-dimetoxifenil)oxazol-4-il]etil}-2-etoxibenzamida, (244) N-(2-oxo-2-feniletil)-2-(3,4-dietoxifenil)oxazol-4-carboxamida, (245) 1-(4-{4-[2-(3,4-dietoxifenil)oxazol-4-carbonil]piperazin-1-il}fenil)etanona, (246) 4-(2-(3,4-dietoxi-fenil)oxazol-4-il)-1-(4-metoxifenil)piperazina, (247) 4-(2-(3,4-dietoxifenil)-oxazol-4-il)-1-(4-hidroxifenil)piperazina, (248) N-fenetil-2-(3,4-dimetoxifenil)oxazol-4-carboxamida, (249) N-(2-(pirrolidin-1-il)etil)-2-(3,4-dimetoxifenil)oxazol-4-carboxamida, (250) 2-[2-(3,4-dietoxifenil)-oxazol-4-il]-N-(2-etoxifenil)acetamida, (251) 2-[2-(3,4-dietoxifenil)oxazol-4-il]-N-(3-hidroxipiridin-2-il)acetamida, (252) 4-[2-(3,4-dietoxifenil)oxazol-4-ilmetil]piperazin-2-ona, (253) 4-[2-(3,4-dietoxifenil)oxazol-4-ilmetil]morfolina, (254) 2-[2-(3,4-dietoxifenil)oxazol-4-ilmetilsulfanil]-piridina, (255) 2-[2-(3,4-dietoxifenil)oxazol-4-ilmetanosulfonil]piridina, (256) N-[2-(3,4-dietoxifenil)oxazol-4-ilmetil]-2-metilbencenosulfonamida, (257) 2-(3-ciclopropilmetoxi-4-metoxifenil)-4-[3-(2-etoxifenil)propil]oxazol, (258) 2-(3-hidroxi-4-metoxifenil)-4-(3-o-tolilpropil)oxazol, (259) 2-(3-ciclopropilmetoxi-4-metoxifenil)-4-(3-o-tolilpropil)oxazol, (260) 3-[2-(3-ciclopropilmetoxi-4-metoxifenil)oxazol-4-il]-1-(2-etoxifenil)propan-1-ol, (261) 3-[2-(3-isopropoxi-4-metoxifenil)oxazol-4-il]-2,2-dimetil-1-(3-metilpiridin-2-il)propan-1-ona, (262) 3-(3-metoxipiridin-2-il)-2-{2-[4-metoxi-3-(2,2,2-trifluoroetoxi)-fenil]oxazol-4-ilmetil}-3-oxopropionato, (263) 2-{2-[4-metoxi-3-(2,2,2-trifluoroetoxi)-fenil]-oxazol-4-ilmetil}-2-metil-3-(3-metilpiridin-2-il)-3-oxopropionato, (264) 1-(3-metoxipiridin-2-il)-3-{2-[4-metoxi-3-(2,2,2-trifluoroetoxi)fenil]oxazol-4-il}-2-metilpropan-1-ona, (265) 1-(3-metoxipiridin-2-il)-3-{2-[4-metoxi-3-(2,2,2-trifluoroetoxi)-fenil]oxazol-4-il}-2,2-dimetilpropan-1-ona, (266) 3-[2-(3-benciloxi-4-metoxifenil)oxazol-4-il]-1-(2-hidroxifenil)propan-1-ona como, (267) 3-[2-(3-benciloxi-4-metoxi-fenil)oxazol-4-il]-1-(2-difluorometoxifenil)propan-1-ona, (268) 3-[2-(3-benciloxi-4-metoxifenil)oxazol-4-il]-1-[2-(2-fluoro-etoxi)fenil]propan-1-ona, (269) 3-[2-(3-benciloxi-4-metoxifenil)oxazol-4-il]-1-[2-(2,2-di-fluoroetoxi)fenil]propan-1-ona, (270) 1-(2-difluorometoxifenil)-3-[2-(3-hidroxi-4-metoxifenil)-oxazol-4-il]propan-1-ona, (271) 1-[2-(2-fluoroetoxi)fenil]-3-[2-(3-hidroxi-4-metoxifenil)-oxazol-4-il]propan-1-ona, (272) 1-[2-(2,2-difluoroetoxi)fenil]-3-[2-(3-hidroxi-4-metoxi-fenil)oxazol-4-il]propan-1-ona, (273) 1-(2-difluorometoxifenil)-3-[2-(3-isopropoxi-4-metoxifenil)oxazol-4-il]propan-1-ona, (274) 1-(2-difluorometoxifenil)-3-[2-(3-etoxi-4-metoxifenil)oxazol-4-il]propan-1-ona, (275) 1-(2-fluoroetoxifenil)-3-[2-(3-isopropoxi-4-metoxifenil)oxazol-4-il]propan-1-ona, (276) 3-[2-(3-but-3-eniloxi-4-metoxifenil)oxazol-4-il]-1-[2-(2-fluoroetoxi)fenil]propan-1-ona, (277) 1-[2-(2-fluoroetoxi)fenil]-3-[2-(3-isobutoxi-4-metoxifenil)oxazol-4-il]propan-1-ona, (278) 1-[2-(2,2-difluoroetoxi)fenil]-3-[2-(3-isopropoxi-4-metoxifenil)oxazol-4-il]propan-1-ona, (279) 1-[2-(2,2-difluoroetoxi)fenil]-3-[2-(3-propoxi-4-metoxifenil)oxazol-4-il]propan-1-ona, (280) 1-[2-(2,2-difluoroetoxi)fenil]-3-[2-(3-etoxi-4-metoxifenil)oxazol-4-il]propan-1-ona, (281) 3-[2-(3-aliloxi-4-metoxifenil)oxazol-4-il]-1-[2-(2,2-difluoroetoxi)fenil]propan-1-ona, (282) 3-[2-(3-but-3-eniloxi-4-metoxifenil)oxazol-4-il]-1-[2-(2,2-difluoroetoxi)fenil]propan-1-ona, (283) 3-[2-(3-ciclopropilmetoxi-4-metoxifenil)oxazol-4-il]-1-[2-(2,2-difluoroetoxi)fenil]propan-1-ona, (284) 3-{2-[3-(2,2-difluoroetoxi)-4-metoxifenil]oxazol-4-il}-1-[2-(2,2-difluoroetoxi)fenil]propan-1-ona, (285) 1-[2-(2,2-difluoroetoxi)fenil]-3-[2-(3-isobutoxi-4-metoxifenil)oxazol-4-il]propan-1-ona, (286) 3-[2-(3,4-dietoxifenil)oxazol-4-il]-1-(2-metoximetoxi-fenil)propan-1-ona, (287) 3-[2-(3,4-dietoxifenil)oxazol-4-il]-1-(2-hidroxifenil)propan-1-ona, (288) 3-[2-(3,4-dietoxifeniloxazol-4-il)-1-(2-difluorametoxifenil)propan-1-ona, (289) 3-[2-(3,4-dietoxifenil)oxazol-4-il]-1-[2-(2-fluoroetoxi)-fenilo]propan-1-ona, (290) 3-[2-(3,4-dietoxifenil)oxazol-4-il]-1-[2-(2,2-difluoroetoxi)-fenil]propan-1-ona, (291) 2-{3-[2-(3-isopropoxi-4-metoxifenil)oxazol-4-il]propionil}fenilo, (292) 3-[2-(3,4-dietoxifenil)oxazol-4-il]-1-(2-trifluoro-metoxifenil)propan-1-ona, (293) 3-[2-(3-ciclopropilmetoxi-4-metoxifenil)oxazol-4-il]-1-(2-trifluoro-metoxifenil)propan-1-ona, (294) 3-[2-(3,4-dietoxifenil)oxazol-4-il]-1-(2,5-dimetoxifenil)-propan-1-ona, (295) 3-[2-(3,4-dietoxifenil)oxazol-4-il]-1-(2-etoxi-5-metilfenil)-propan-1-ona, (296) 3-[2-(3,4-dietoxifenil)oxazol-4-il]-1-(2,4-dimetilfenil)-propan-1-ona, (297) 3-[2-(3,4-dietoxifenil)oxazol-4-il]-1-(2,5-dimetilfenil)-propan-1-ona, (298) 3-[2-(3,4-dietoxifenil)oxazol-4-il]-1-(2-etoxi-4-metilfenil)-propan-1-ona, (299) 3-[2-(3,4-dietoxifenil)oxazol-4-il]-1-(2-etoxi-4-fluorofenil)-propan-1-ona, (300) 3-[2-(3,4-dietoxifenil)oxazol-4-il]-1-(2-metoximetilfenil)-propan-1-ona, (301) 3-[2-(3,4-dietoxifenil)oxazol-4-il]-1-(2-etilofenil)propan-1-ona, (302) 3-[2-(3,4-dietoxifenil)oxazol-4-il]-1-(2,3-dimetoxifenil)-propan-1-ona, (303) 3-[2-(3,4-dietoxifenil)oxazol-4-il]-1-(2-etoxi-3-metilfenil)-propan-1-ona, (304) 1-(2-etoxi-4-fluorofenil)-3-[2-(3-etoxi-4-metoxifenil)oxazol-4-il]propan-1-ona, (305) 3-[2-(3-etoxi-4-metoxifenil)oxazol-4-il]-1-(4-fluoro-2-isopropoxi-fenil)propan-1-ona, (306) 1-(2-etoxi-5-metilofenil)-3-[2-(3-isopropoxi-4-metoxifenil)oxazol-4-il]-propan-1-ona, (307) 1-(2-etoxi-4-metilfenil)-3-[2-(3-isopropoxi-4-metoxifenil)oxazol-4-il]-propan-1-ona, (308) 3-[2-(3-difluorometoxi-4-metoxifenil)oxazol-4-il]-1-(3-metilpiridin-2-il)propan-1-ona, (309) 3-{2-[3-(2,2-difluoroetoxi)-4-metoxifenil]oxazol-4-il}-1-(3-metilpiridin-2-il)propan-1-ona, (310) 3-{2-[3-(2-fluoroetoxi)-4-metoxifenil]oxazol-4-il}-1-(3-metil-piridin-2-il)propan-1-ona, (311) 3-[2-(3-sec-butoxi-4-metoxifenil)-oxazol-4-il]-1-(3-metilpiridin-2-il)propan-1-ona, (312) 3-{2-[3-(1-etilopropoxi)-4-metoxi-fenil]oxazol-4-il}-1-(3-metilpiridin-2-il)propan-1-ona, (313) 3-[2-(3-difluorometoxi-4-metoxifenil)oxazol-4-il]-1-(2-etoxifenil)propan-1-ona, (314) 3-{2-[3-(2,2-difluoroetoxi)-4-metoxifenil]oxazol-4-il}-1-(2-etoxifeni1)propan-1-ona, (315) 1-(2-etoxifenil)-3-{2-[3-(2-fluoroetoxi)-4-metoxifenil]oxazol-4-il}propan-1-ona, (316) 2-{2-[4-benciloxi-3-(2,2-difluoroetoxi)fenil]-oxazol-4-ilmetil}-3-(3-metilpiridin-2-il)-3-oxo-propionato, (317) 3-{2-[3-(2,2-difluoroetoxi)-4-hidroxifenil]oxazol-4-il}-1-(3-metilpiridin-2-il)propan-1-ona, (318) 3-{2-[3-(2,2-difluoroetoxi)-4-etoxifenil]oxazo1-4-il}-1-(3-metilpiridin-2-il)-propan-1-ona, (319) 3-{2-[3-(2,2-difluoroetoxi)-4-isopropoxifenil]oxazol-4-il}-1-(3-metilpiridin-2-il)propan-1-ona, (320) N-[2-(3-benciloxi-4-metoxifenil)oxazol-4-ilmetil]-2-difluorometoxi-benzamida, (321) 2-difluorometoxi-N-[2-(3-hidroxi-4-metoxifenil)oxazol-4-ilmetil]-benzamida, (322) N-[2-(3-aliloxi-4-metoxifenil)-oxazol-4-ilmetil]-2-difluorometoxibenzamida, (323) 2-difluorometoxi-N-[2-(3-isopropoxi-4-metoxifenil)oxazol-4-ilmetil]benzamida, (324) N-{2-[3-(1-etilpropoxi)-4-metoxifenil]oxazol-4-ilmetil}-3-metilpicolinamida, (325) 2-etoxi-N-{2-[3-(1-etilpropoxi)-4-metoxifenil]oxazol-4-ilmetil}benzamida, (326) 2-[2-(3-benciloxi-4-difluorometoxifenil)oxazol-4-ilmetil]-3-(3-metilpiridin-2-il)-3-oxopropionato, (327) 3-[2-(4-difluorometoxi-3-hidroxifenil)oxazol-4-il]-1-(3-metilpiridin-2-il)propan-1-ona, (328) 3-[2-(3-ciclopropilmetoxi-4-difluorometoxifenil)oxazol-4-il]-1-(3-metilpiridin-2-il)propan-1-ona, (329) 3-[2-(4-difluorometoxi-3-propoxifenil)-oxazol-4-il]-1-(3-metilpiridin-2-il)propan-1-ona, (330) 3-[2-(3-aliloxi-4-difluorometoxifenil)-oxazol-4-il]-1-(3-metilpiridin-2-il)propan-1-ona, (331) 3-[2-(3-but-3-eniloxi-4-difluoro-metoxifenil)-oxazol-4-il]-1-(3-metilpiridin-2-il)-propan-1-ona, (332) 3-[2-(4-difluorometoxi-3-isopropoxifenil)oxazol-4-il]-1-(3-metil-piridin-2-il)propan-1
ARP170101905A 2005-11-15 2017-07-10 Compuesto de oxazol y composición farmacéutica AR109007A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2005330590 2005-11-15

Publications (1)

Publication Number Publication Date
AR109007A2 true AR109007A2 (es) 2018-10-17

Family

ID=37879936

Family Applications (3)

Application Number Title Priority Date Filing Date
ARP060104973A AR057891A1 (es) 2005-11-15 2006-11-14 Compuestos de oxazol y composicion farmaceutica
ARP170101905A AR109007A2 (es) 2005-11-15 2017-07-10 Compuesto de oxazol y composición farmacéutica
ARP170101904A AR109006A2 (es) 2005-11-15 2017-07-10 Compuesto de oxazol y composición farmacéutica

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ARP060104973A AR057891A1 (es) 2005-11-15 2006-11-14 Compuestos de oxazol y composicion farmaceutica

Family Applications After (1)

Application Number Title Priority Date Filing Date
ARP170101904A AR109006A2 (es) 2005-11-15 2017-07-10 Compuesto de oxazol y composición farmacéutica

Country Status (22)

Country Link
US (8) USRE46792E1 (es)
EP (1) EP1954684B1 (es)
JP (1) JP5305914B2 (es)
KR (1) KR101439557B1 (es)
CN (1) CN101309912B (es)
AR (3) AR057891A1 (es)
AU (1) AU2006316079B2 (es)
BR (1) BRPI0618589B8 (es)
CA (1) CA2627541C (es)
CY (1) CY1115302T1 (es)
DK (1) DK1954684T3 (es)
ES (1) ES2483992T3 (es)
IL (1) IL191008A (es)
MY (1) MY153720A (es)
NO (1) NO341440B1 (es)
PL (1) PL1954684T3 (es)
PT (1) PT1954684E (es)
RU (1) RU2418793C2 (es)
SI (1) SI1954684T1 (es)
TW (1) TWI330639B (es)
WO (1) WO2007058338A2 (es)
ZA (1) ZA200803758B (es)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4986927B2 (ja) * 2007-05-14 2012-07-25 大塚製薬株式会社 医薬
US9029408B2 (en) 2008-06-16 2015-05-12 Gtx, Inc. Compounds for treatment of cancer
US9447049B2 (en) 2010-03-01 2016-09-20 University Of Tennessee Research Foundation Compounds for treatment of cancer
JP5507552B2 (ja) 2008-06-16 2014-05-28 ユニバーシティ オブ テネシー リサーチ ファウンデーション 癌を処置するための化合物
US8822513B2 (en) 2010-03-01 2014-09-02 Gtx, Inc. Compounds for treatment of cancer
GB2465890A (en) * 2008-12-05 2010-06-09 Scynexis Inc 2-Arylazole derivatives as antiprotozoal agents
JP5879273B2 (ja) 2010-03-01 2016-03-08 ジーティーエックス・インコーポレイテッド 癌を処置するための化合物
CN103002742B (zh) 2010-03-05 2016-07-13 卡尔约药物治疗公司 核转运调节剂及其应用
KR101512548B1 (ko) * 2010-03-12 2015-04-15 오메로스 코포레이션 Pde10 억제제 및 관련 조성물 및 방법
CA2824808A1 (en) 2011-01-17 2012-07-26 Karyopharm Therapeutics, Inc. Olefin containing nuclear transport modulators and uses thereof
KR20200088518A (ko) 2011-07-29 2020-07-22 카리오팜 쎄라퓨틱스, 인코포레이티드 하이드라지드 함유 핵 수송 조절인자 및 이의 용도
JP6006794B2 (ja) 2011-07-29 2016-10-12 カリオファーム セラピューティクス，インコーポレイテッド 核内輸送調節因子およびその使用
US9199975B2 (en) 2011-09-30 2015-12-01 Asana Biosciences, Llc Biaryl imidazole derivatives for regulating CYP17
US8809372B2 (en) 2011-09-30 2014-08-19 Asana Biosciences, Llc Pyridine derivatives
CN104080770A (zh) 2011-11-09 2014-10-01 迈兰实验室有限公司 用于制备罗氟司特的改进方法
HUE040427T2 (hu) 2012-05-09 2019-03-28 Biogen Ma Inc Nukleáris transzportmodulátorok és felhasználásuk
WO2014034958A1 (en) 2012-08-30 2014-03-06 Otsuka Pharmaceutical Co., Ltd. Method for producing oxazole compound
EP2968278B8 (en) 2013-03-15 2019-05-22 Karyopharm Therapeutics Inc. Methods of promoting wound healing using crm1 inhibitors
MX365939B (es) 2013-06-21 2019-06-19 Karyopharm Therapeutics Inc Moduladores del transporte nuclear y usos de los mismos.
CN105085429B (zh) * 2014-04-25 2019-12-10 广东东阳光药业有限公司 芳杂环类衍生物及其在药物上的应用
NZ716494A (en) 2014-04-28 2017-07-28 Omeros Corp Processes and intermediates for the preparation of a pde10 inhibitor
NZ630803A (en) 2014-04-28 2016-03-31 Omeros Corp Optically active pde10 inhibitor
SG11201700789SA (en) 2014-08-15 2017-02-27 Karyopharm Therapeutics Inc Polymorphs of selinexor
TWI689497B (zh) * 2014-09-04 2020-04-01 南北兄弟藥業投資有限公司 芳雜環類衍生物及其在藥物中的應用
AU2016250843A1 (en) 2015-04-24 2017-10-12 Omeros Corporation PDE10 inhibitors and related compositions and methods
CN106188027B (zh) * 2015-09-02 2020-10-20 广东东阳光药业有限公司 芳杂环类衍生物及其在药物中的应用
WO2017079678A1 (en) 2015-11-04 2017-05-11 Omeros Corporation Solid state forms of a pde10 inhibitor
TWI726027B (zh) * 2015-12-28 2021-05-01 日商大塚製藥股份有限公司 軟膏
CN106279138B (zh) * 2015-12-29 2019-03-01 广东东阳光药业有限公司 芳杂环类衍生物及其在药物中的应用
US10709706B2 (en) 2015-12-31 2020-07-14 Karopharm Therapeutics Inc. Nuclear transport modulators and uses thereof
US10526295B2 (en) 2015-12-31 2020-01-07 Karyopharm Therapeutics Inc. Nuclear transport modulators and uses thereof
US11602530B2 (en) 2016-11-28 2023-03-14 Biogen Ma Inc. CRM1 inhibitors for treating epilepsy
SG11202009564TA (en) * 2018-04-04 2020-10-29 Otsuka Pharma Co Ltd Oxazole compound crystal
TW202227424A (zh) * 2020-11-27 2022-07-16 大陸商瑞石生物醫藥有限公司 芳基或雜芳基取代５員芳雜環化合物及其用途
CN112425610A (zh) * 2021-01-22 2021-03-02 深圳市洛奇机电科技有限公司 一种防治君子兰叶斑病的农药悬浮剂的制备系统及其应用
JPWO2023182468A1 (es) 2022-03-25 2023-09-28
CN115785014B (zh) * 2022-12-27 2025-01-24 瑞石生物医药有限公司 四唑衍生物及其用途
GB202306663D0 (en) 2023-05-05 2023-06-21 Union Therapeutics As Combination therapy
WO2025249530A1 (en) 2024-05-29 2025-12-04 Otsuka Pharmaceutical Co., Ltd. Difamilast-containing composition

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4735961A (en) * 1984-05-07 1988-04-05 Merck & Co., Inc. Oxazoles and thiazoles containing an aminohydroxypropoxyphenyl moiety
MX15171A (es) * 1988-03-08 1993-05-01 Pfizer Derivados de tiazolidinodiona hipoglicemicos
US5814651A (en) * 1992-12-02 1998-09-29 Pfizer Inc. Catechol diethers as selective PDEIV inhibitors
US20020169173A1 (en) 1993-11-08 2002-11-14 Smithkline Beecham Corporation Oxazoles for treating cytokine mediated diseases
WO1996000218A1 (en) 1994-06-24 1996-01-04 Euro-Celtique, S.A. Compounds for and method of inhibiting phosphodiesterase iv
AUPO156596A0 (en) 1996-08-09 1996-09-05 University Of Sydney, The Synthetic polynucleotides
DE19632549A1 (de) 1996-08-13 1998-02-19 Merck Patent Gmbh Arylalkanoylpyridazine
AU4015497A (en) * 1996-08-26 1998-03-19 Byk Gulden Lomberg Chemische Fabrik Gmbh Thiazole derivatives useful as selective inhibitors of pde-iv
NZ335610A (en) 1996-10-07 2000-10-27 Lilly Co Eli Phenyl oxazoles, thiazoles, oxazolines, oxadiazoles and benzoxazole compounds useful as neuro-protective agents
US6020339A (en) 1997-10-03 2000-02-01 Merck & Co., Inc. Aryl furan derivatives as PDE IV inhibitors
JP4518587B2 (ja) 1998-03-09 2010-08-04 興和創薬株式会社 ２−フェニルモルホリン誘導体
AR036237A1 (es) * 2001-07-27 2004-08-25 Bayer Corp Derivados del acido indan acetico, intermediarios, y metodo para su preparacion, composicion farmaceutica y el uso de dichos derivados para la manufactura de un medicamento
EP1435944B1 (en) 2001-10-16 2009-09-30 Memory Pharmaceutical Corporation 4(4-alkoxy-3-hydroxyphenyl)-2-pyrrolidone derivatives as pde-4 inhibitors for the treatment of neurological syndromes
WO2003072102A1 (en) 2002-02-25 2003-09-04 Eli Lilly And Company Peroxisome proliferator activated receptor modulators
JP2004203871A (ja) * 2002-12-13 2004-07-22 Yamanouchi Pharmaceut Co Ltd 医薬組成物
TW200505913A (en) 2003-03-28 2005-02-16 Hoffmann La Roche Novel oxazole derivatives, their manufacture and use as pharmaceutical agents
WO2005111007A1 (ja) 2004-05-17 2005-11-24 Otsuka Pharmaceutical Co., Ltd. チアゾール化合物及びその用途
DK1786790T3 (da) 2004-07-26 2009-07-20 Lilly Co Eli Oxazolderivater som histamin H3 receptorstoffer, fremstilling og terapeutiske anvendelser
DE102004051277A1 (de) * 2004-10-21 2006-04-27 Merck Patent Gmbh Heterocyclische Carbonylverbindungen
EP1866293A1 (en) * 2005-03-31 2007-12-19 UCB Pharma, S.A. Compounds comprising an oxazole or thiazole moiety, processes for making them, and their uses

Also Published As

Publication number Publication date
US20090221586A1 (en) 2009-09-03
TWI330639B (en) 2010-09-21
US20220265613A1 (en) 2022-08-25
NO341440B1 (no) 2017-11-13
NO20081930L (no) 2008-06-10
CA2627541C (en) 2014-12-30
US20190070151A1 (en) 2019-03-07
AR109006A2 (es) 2018-10-17
ZA200803758B (en) 2009-08-26
IL191008A (en) 2013-10-31
SI1954684T1 (sl) 2014-07-31
US8637559B2 (en) 2014-01-28
WO2007058338A9 (en) 2007-08-30
US20200078340A1 (en) 2020-03-12
AR057891A1 (es) 2007-12-26
KR101439557B1 (ko) 2014-09-11
WO2007058338A2 (en) 2007-05-24
ES2483992T3 (es) 2014-08-08
CN101309912A (zh) 2008-11-19
MY153720A (en) 2015-03-13
JP5305914B2 (ja) 2013-10-02
AU2006316079B2 (en) 2012-03-29
DK1954684T3 (da) 2014-06-30
PL1954684T3 (pl) 2014-10-31
EP1954684A2 (en) 2008-08-13
BRPI0618589B8 (pt) 2021-05-25
USRE46792E1 (en) 2018-04-17
EP1954684B1 (en) 2014-05-07
TW200732332A (en) 2007-09-01
CA2627541A1 (en) 2007-05-24
BRPI0618589A2 (pt) 2012-07-03
BRPI0618589B1 (pt) 2020-11-17
US20240148699A1 (en) 2024-05-09
PT1954684E (pt) 2014-07-17
HK1121162A1 (en) 2009-04-17
US20170216260A1 (en) 2017-08-03
US20140100226A1 (en) 2014-04-10
WO2007058338A3 (en) 2007-07-19
CY1115302T1 (el) 2017-01-04
RU2418793C2 (ru) 2011-05-20
RU2008123839A (ru) 2009-12-27
AU2006316079A1 (en) 2007-05-24
JP2009515872A (ja) 2009-04-16
CN101309912B (zh) 2013-09-25
KR20080073337A (ko) 2008-08-08

Similar Documents

Publication Publication Date Title
AR109007A2 (es) Compuesto de oxazol y composición farmacéutica
NZ600084A (en) Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
RU2312101C2 (ru) Цис-имидазолины в качестве ингибиторов mdm2
RU2383524C2 (ru) Гексафторизопропанол-замещенные производные простых эфиров
WO2006103045B1 (en) Compounds comprising an oxazole or thiazole moiety, processes for making them, and their uses
ES2290439T3 (es) Moduladores del receptor activado del proliferador de peroxisomas.
CN1235870C (zh) 苯基杂烷基胺衍生物的新应用
CN1289467C (zh) 二苄胺化合物及其药物用途
JP2011518774A5 (es)
ES2617221T3 (es) Derivados de 3-(2-aril-cicloalquenilmetil)-oxazolidin-2-ona como inhibidores de la proteína de transferencia de ésteres de colesterol (CETP)
CN1252713A (zh) 作为基质金属蛋白酶抑制剂的n－羟基－2－(烷基、芳基或杂芳基硫烷基、亚磺酰基或磺酰基)－3－取代的烷基,芳基或杂芳基酰胺
RU2001126559A (ru) Активаторы глюкокиназы
HRP20151060T1 (hr) 4-aril-n-fenil-1,3,5-triazin-2-amini koji sadrže sulfoksimin skupinu
US7138425B2 (en) Phthalimide carboxylic acid derivatives
CA2558585A1 (en) Compounds, pharmaceutical compositions and methods for use in treating metabolic disorders
CN1578659A (zh) 过氧化物酶体增殖剂激活的受体(ppar)的调节剂
JP2004509084A5 (es)
CA2494695A1 (en) 2-(3-aminoaryl)amino-4-aryl-thiazoles and their use as c-kit inhibitors
RU2007137987A (ru) Цис-2, 4, 5-триарилимидазолины и их применение в качестве противораковых лекарственных средств
RU2009144113A (ru) Ингибиторы фермента диацилглицерин о-ацилтрансферазы типа 1
CA2719000A1 (en) Piperidine derivatives as inhibitors of stearoyl-coa desaturase
CN1358179A (zh) 噻唑和噁唑衍生物以及它们的药物应用
CN1334798A (zh) 苯基甘氨酸衍生物
JP2007525516A5 (es)
CN1826106A (zh) 皮肤色素沉着的治疗剂

Legal Events

Date Code Title Description
FB Suspension of granting procedure